Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer

Su, Shishuai; Ding, Yanping; Li, Yiye; Wu, Yan; Nie, Guangjun

doi:10.1016/j.biomaterials.2015.11.058

Cited by 88 publications

(55 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatment modalities for TNBC are limited to surgery, radiation and systemic chemotherapy because of the lack of more specific therapeutic targets [17]. Over the past few decades, tremendous efforts have been expended in searching for a molecular targeted therapy for TNBC and with limited success [18].…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

Zhao

Liu

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a highly aggressive tumour subtype associated with poor prognosis. The mechanisms involved in TNBC progression remains largely unknown. To date, there are no effective therapeutic targets for this tumour subtype. Paired-related homeobox 1b (Prrx1b), one of major isoforms of Prrx1, has been identified as a new epithelial-mesenchymal transition (EMT) inducer. However, the function of Prrx1b in TNBC has not been elucidated. In this study, we found that Prrx1b was significantly up-regulated in TNBC and associated with tumour size and vascular invasion of breast cancer. Silencing of Prrx1b suppressed the proliferation, migration and invasion of basal-like cancer cells. Moreover, silencing of Prrx1b prevented Wnt/b-catenin signaling pathway and induced the mesenchymal-epithelial transition (MET). Taken together, our data indicated that Prrx1b may be an important regulator of EMT in TNBC cells and a new therapeutic target for interventions against TNBC invasion and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

Zhao

Liu

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…PTT has shown promise as an alternative strategy for TNBC therapy, [4][5][6][7]9 and here we aimed to expand this potential by creating a biodegradable NP platform that enables proapoptotic PTT. The key advantage of PTT relative to other therapies is its high precision, as the use of tissue-penetrating NIR light as an activating source means that heat is produced only where this light and photoresponsive NPs are combined within tumors.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 This lack of expression makes TNBC unsusceptible to current targeted or hormonal therapies and results in high recurrence and mortality rates. [1][2][3] Several alternative treatment strategies have shown promise against TNBC, including photothermal therapy (PTT), [4][5][6][7] which utilizes nanoparticles (NPs) embedded in tumors as exogenous energy absorbers to convert externally applied near-infrared (NIR) light into heat to ablate cancer cells. [8][9][10] In NP-mediated PTT, NPs delivered systemically accumulate in tumors through their leaky vasculature, 11,12 and are then irradiated with NIR light, which causes them to produce heat sufficient to induce tumor cell death.…”

Section: Introductionmentioning

confidence: 99%

IR820‐loaded PLGA nanoparticles for photothermal therapy of triple‐negative breast cancer

Valcourt

Dang

Day

2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) accounts for 15–25% of breast cancer cases and lacks expression of the three most common receptors seen on other subtypes of breast cancer. This lack of expression makes TNBC unsusceptible to currently available targeted or hormonal therapies, so new treatment strategies are desperately needed. Photothermal therapy (PTT), which utilizes nanoparticles (NPs) embedded in tumors as exogenous energy absorbers to convert externally applied near‐infrared (NIR) light into heat to ablate cancer cells, has shown promise as an alternative strategy. However, it typically uses gold‐based NPs that will remain in the body for extended period of time with unknown long‐term health effects. To enable PTT with biodegradable, polymeric NPs, we encapsulated the NIR‐absorbing dye IR820 in poly(lactic‐co‐glycolic acid) (PLGA) NPs. We characterized the physicochemical properties of these IR820‐loaded PLGA NPs and evaluated their performance as PTT agents using both in vitro and in vivo models of TNBC. The results demonstrate that these NPs are potent mediators of PTT that induce cell death primarily through apoptosis to effectively hinder the growth of TNBC tumors. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1702–1712, 2019.

show abstract

“…Therefore, chemotherapy is the only option for these advanced pancreatic cancer patients. 4 Lymph node metastasis is the main metastatic pattern of pancreatic cancer, which directly leads to the cancer death. 5 Therefore, it is of vital importance to identify new strategy to locate the sentinel lymph node (SLN), which is the first target in early-stage cancer metastases, and then eradicate metastatic cancer cells in this SLN to prevent further cancer metastases.…”

Section: Introductionmentioning

confidence: 99%

Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases

Yu¹,

Zhu²,

Yang³

et al. 2017

IJN

View full text Add to dashboard Cite

Lymphatic metastasis is the major metastatic pattern of pancreatic cancer and considered as an independent risk factor of survival. However, there is still no effective way for the diagnosis and treatment for lymphatic metastases of pancreatic cancer. In this study, using albumin as a carrier of gemcitabine (Gem), further modified by pyropheophorbide-a, we have designed and synthesized a nanoparticle (NP) compound named “pheophorbide-a (P@)-Gem-human serum albumin (HSA)-NPs”. By utilization of its tracer ability of lymphatic metastases, which is triggered by near-infrared irradiation and its visible dying ability, the compound is used for drug delivery tracking, meanwhile as a treating drug, as well as the combined effect of photodynamic therapy and chemotherapy. By the nude mice model of lymphatic metastases of pancreatic cancer (BxPC-3-LN7), we aim to explore the feasibility, effectiveness, and biological safety of diagnosis and treatment for the lymphatic metastases of pancreatic cancer by P@-Gem-HSA-NP, thereby, providing new methods and strategies for the study of nanodrug carrier and research on lymphatic metastases of pancreatic cancer.

show abstract

Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer

Cited by 88 publications

References 34 publications

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

IR820‐loaded PLGA nanoparticles for photothermal therapy of triple‐negative breast cancer

Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases

Contact Info

Product

Resources

About